Intellicell Biosciences Inc (fka SVFC)

[mave_rick]

Investors SVFC Is Your Goldmine

Happy Saturday Investors and Please Understand I am Speaking to INVESTORS Not Traders Or "Timers" Or Flippers.

If you have the Ability to look at a Minimum Of 6-12 Months When You Analyze The Risk/Reward Ratios That will Weigh In To help You make an INVESTMENT Decision , Then It Makes Complete Sense to Buy As Much SVFC as Possible Given Your Personal Risk Tolerance Levels and Investment Objectives.

First Technically Speaking, Look even with a Rough Raw Look at the 6-9-12 Month Charts and You will see That SVFC was VOLATILE as Most ALL Bio Tech Stocks are , and Yes Even The HUGE Names In this Industry Show VOLATILITY and this VOLATILITY is Your FRIEND With SVFC. Remember this that at these RIDICULOUS Price Levels of .003-.004 ( as Of January 17, 2013 ), Our Risk Reward Ratios are HIGHLY In The Favor Of LONGS NOT shorts. Can You see the 6-9-12 Month Charts and See that Clearly? If You are an INVESTOR, You can See This:):)

More Specifically, You will Observe that when You look at July through December 2013, The Price Just a Short six months ago in Mid July was as High as .075 and ACCEPT the TRUTH that The MAIN ( Although Not the Only ) Reason was the Iron Ridge Toxic Sewage News and NOT some HUGE Fundamental Shift or Disappointment Or Change In FUNDAMENTALS. So ask Yourself this Question, " Can we Reasonably Expect this IR Toxicity To Be Flushed Out of the Equation this Year?" When Evaluating the Valuation of SVFC. If You are an REASONABLE Unbiased INVESTOR, You Must Conclude that SVFC is a HUGE STRONG BUY at these Price Levels. Then Ask Yourself if a Price of .075 is a GREAT RETURN If Your BUY PRICE is .003-.004. I Don't Think I have to do that Math and Tell you that ANY INVESTOR would Welcome a Return OVER 2000%:):)

Notice That the Price was as low as low as .01 right before Mid June 2012 and then in mid July the PPS was at .075. VOLATILITY is Your Friend. But Remember INVESTORS, While the People who Invested at higher prices have had and still have Ample chances to Average Down their Cost Basis Significantly at these Price levels , YOU as an INVESTOR are looking Perhaps for the First Time at SVFC OR Perhaps you have been watching it but just Now are Looking at it Seriously Since It will be on Many Radar Screens after Over a Volume of 237 Million Shares Traded Friday. I was such an INVESTOR. I am Preaching what I PRACTICED Myself. This is a Great time to give you a Disclaimer that I am a STRONG LONG and Bought 15 Million Shares in the .003's Friday and this was My First and easily Not the Last Purchase of SVFC Shares.

Last, You can take a Look at the 6-9-12 Month Charts Yourself as well, But Notice that less than a year ago in February 2013, the Stock price hit a High Of 20 cents and then again in very late April 2013 It Hit a High of 19 cents.

Have the Fundamentals Changed? Yes The Fundamental Progress In Applying for Several Patents and Studies showing a Clear and Distinct Benefit using the Technology that SVFC has Over their Competing Technologies Like Cytori Is Self Evident. In Fact Over TEN (10) Times better.

Refer to This From an Earlier Post.

" Quote:
www.forbes.com/sites/genemarcial/2011/08/28/human-bodys-fat-seen-as-best-source-of-stem-cells-for-regenerative-therapies/

A study of IntelliCell’s technology by Millipore, a division of Merck AG of Germany, confirmed that it produced an average of 10 times the number of SVF cells containing adult adipose stem cells from less than which the company believes is used by any of its present competition that use enzymes in their process. The study also showed that the SVF cells produced by IntelliCell contain all of the viable cells that are manufactured by competing technologies that use enzymes, such as Cytori. "


Next, I wanted to bring the Issue Of Dilution Up. NOT ALL Dilution is Bad. If You Can clearly see a Balanced and Relative Relationship with the Company Issuing shares and then Clear Fundamental Progress as will be soon Evidenced with the passing of the International Patent and clearing the path for SVFC to do Business in Several European Countries, and You See The Shareholder Letter By the CEO Steven Victor, You can See the Company's Vision and Strategy Outlined for 2014.

Looking at the Outstanding shares, I feel the OS may be at Between 400-500 MM as a Maximum Right Now although I have no way of Confirming an Exact Count at this Point in Time. A Count of 500 MM Shares as OS, a PPS of .0032 Puts the market Cap at $1.6 MM and at a count of 400 MM OS the Market Cap is $1.28 MM. These Market Caps Show a Clear and TOTAL UNDERVALUATION Of SVFC Shares In My Opinion, Due to NOW Publicly Known Negative Catalysts like the IR Case that Most NOW Reasonably Expect to be RESOLVED Fairly Quickly, If Not Next Week Then Soon thereafter even if the Court does Give another Extension Just as a Mere Speculation On My Part. Nevertheless, I Believe that this Toxic IR Catalyst will be a Non Issue Soon and the Price of SVFC Shares Will See a Potentially Radical Upward Price Adjustment to previous levels Before this "Nonsense" Started In July 2013 Approximately when the shares were trading at over 7 cents.

This is an Interesting Post By a Great Contributor Stervc at
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90805557

Comparing SVFC and CYTX

" First, observe below as a study from Merck confirmed that the SVFC (IntelliCell) stem cell process was 10 times greater than Cytori which trades on the NASDAQ under the ticker of CYTX at $2.60+ per share"

He wrote

"CYTX = $2.60+ per share
SVFC = .018+ per share

CYTX Outstanding Shares (OS) = 67,183,050 shares
SVFC Outstanding Shares (OS) = 150,000,000 shares

CYTX Market Cap = $174,675,930 as of currently Aug 8 2013
SVFC Market Cap = $2,700,000 as of currently Aug 8, 2013"


The PPS of SVFC is Now .0032 as of Last Friday January 17, 2013 and the OS count is More Likely 400-500 MM ( My Guess NOT ACCURATE But I am Erring On the side of Caution) The PPS Of CYTX is as of Last Friday $3.05 Per share.

" CYTX Outstanding Shares (OS) = 67,183,050 shares
SVFC Outstanding Shares (OS) = 150,000,000 shares

CYTX Market Cap = $174,675,930 as of currently Aug 8 2013
SVFC Market Cap = $2,700,000 as of currently Aug 8, 2013"


So Todays Approx Market Cap For CYTX is at $205 MM.
Assuming 450 MM Average OS and closing PPS of .0032 The Market Cap for SVFC today is at $1.44 MM

So the Market Cap For CYTX is Approx At OVER 142 Times the Market Cap for SVFC whilst the Technology of SVFC is TEN Times Better that The Cytori Technology. So using the same Rationale as used Initially By Stevc, SVFC shares , Because their Technology is Proving to Perform TEN times Better, Should Be Reasonably Expected to be Priced at 142 Times their Current Price of .0032 which is Over .45 ( 45 Cents)

INVESTORS, Looking at SVFC Technically and Fundamentally, I hope I have shown You At Least Enough To See that SVFC is a Clear BUY BUY BUY At these Prices. It is Impossible to share ALL The DD On SVFC in One Post and If You look at the DD in the Stickies By Poster ITMD and others You will come to the same Conclusion as I did and that is If You are an INVESTOR, SVFC is a STRONG BUY.



NEW INVESTORS Can Read The December 10, 2013 Letter By the CEO Here


" NEW YORK, NY--(Marketwired - Dec 10, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, provides shareholder update.


Dear Valued Shareholders,

On behalf of myself, the Board of Directors and the entire IntelliCell team, I would like to let you know that we are pleased with the growth initiatives that we have accomplished since our initial shareholder letter.

Now is an important and exciting time for IntelliCell Biosciences. We have continued to improve our competitive position in the regenerative medicine field and I believe we have never been stronger or better positioned for future growth. The worldwide regenerative medicine market is being driven by previously unseen treatments and procedures that are improving the quality of life of patients around the world and we firmly believe that we will emerge as one of the leaders in this industry.

The Company has been executing on our strategic plan and business priorities this year. We have made advancements in our technology and have filed patents around the world for our proprietary regenerative medical solutions. I am encouraged by the expanding market presence of IntelliCell Biosciences and the escalating acceptance of the Company's products and solutions within the medical, scientific and investment community. Additionally, we continue to work hard at improving our balance sheet and financial position, in order to have the necessary resources to take advantage of our growth opportunities. Because of all these accomplishments, I believe we are better positioned than ever for growth.

We have focused primarily on three strategic initiatives, Growth, Leverage, and Financial Strength, in order to improve the overall standing of the company.

Growth: We will continue to grow and supply our cellular product to physicians to treat their patients with clinical needs. We intend to be a major provider of minimally manipulated stromal vascular fraction cells SVFCs for autologous use to physicians and achieve exciting clinical results that improve the quality of life for their patients.

Leverage: We are leveraging our scale and best practices to create a cost-effect business model that increases our competitive advantage over our industry peers. Our intent is to open 3 additional facilities in 3 states in the next 12 months. Once the model is perfected, we will roll out additional facilities at a more aggressive pace. As the regenerative medical market expands, we intend to be the most recognized name in the industry.

Financial Strength: We have a goal of improving our balance sheet and income statement in order to deliver strong shareholder returns. Currently we are enacting a plan to remove all debt from our balance sheet. Going forward, it is our intent to use equity capital for the advancement of our company. Believing that IntelliCell Biosciences stock is undervalued, I will be converting a portion of my debt into shares and will continue this practice going forward. These measures will enable us to continue implementing our business and open new Cellular Labs in hospitals and ambulatory surgical centers that will significantly increase our revenues.

We are committed to advance the regenerative medicine field. This will enable us to become more productive, reliable and cost effective than ever before. IntelliCell's physician partners have informed us that we are well-aligned with their strategic intentions, and their clinical and business priorities. These are the key priorities that will ensure IntelliCell's future success.

As many of you know, our technology is new and cutting edge and requires acceptance by the marketplace and the regulators. We will remain aggressive in our efforts to overcome industry obstacles so that our medical solutions can serve as the industry standard. The Company has successfully developed advanced medical technologies, most notably its patented process of isolating SVFCs from adipose (fat) tissue using a mechanical technique, exclusive to the industry of regenerative medicine, now being used by physicians to treat patients with previously unmet clinical needs.

Management firmly believes that regenerative medicine is the future of medicine and we intend to aggressively expand our market footprint in order to solidify our position as the leader in the field. We would like to express our gratitude to our loyal global customer base and we are grateful to our shareholders for their continued support and ownership in our company. As CEO and Founder of IntelliCell, my paramount responsibility is to enhance shareholder value. I take immense pride in the success of this company to date and remain committed to delivering the best products and services possible to increase market presence in the future.

We at IntelliCell Biosciences are confident that our vision and goals will be achieved.

Sincerely,

Dr. Steven Victor
Chief Executive Officer
IntelliCell Biosciences, Inc."


Everything is In My Opinion Only and You should Always take Personal responsibility for All Your Investment decisions and Choices and Always make them Based on Your Own Risk Tolerance level and Investment Objectives.

Happy INVESTING and Good Luck.